Voloridge Investment Management
ITCI

Voloridge Investment Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Voloridge Investment Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,093,738
Closed -$144M – 1440
2025
Q1 		$144M Buy
+1,093,738
New +$136M 0.53% 21
2023
Q4 		– Sell
-49,887
Closed -$2.6M – 1543
2023
Q3 		$2.6M Buy
+49,887
New +$2.91M 0.01% 850
2022
Q3 		– Sell
-92,506
Closed -$5.28M – 1653
2022
Q2 		$5.28M Buy
+92,506
New +$5.25M 0.03% 653
2020
Q4 		– Sell
-29,078
Closed -$746K – 1624
2020
Q3 		$746K Buy
+29,078
New +$663K 0.01% 1015
2020
Q2 		– Sell
-45,043
Closed -$692K – 1555
2020
Q1 		$692K Sell
45,043
-66,462
-60% -$1.44M 0.02% 616
2019
Q4 		$3.83M Buy
111,505
+76,139
+215% +$914K 0.07% 340
2019
Q3 		$264K Buy
+35,366
New +$339K ﹤0.01% 955
2015
Q4 		– Sell
-50,270
Closed -$2.01M – 328
2015
Q3 		$2.01M Buy
+50,270
New +$1.64M 0.09% 179

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Voloridge Investment Management's ITCI Position: Q2 2025 in Review

Voloridge Investment Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 1,093,738 shares — an estimated $144M sold.

Voloridge Investment Management first reported a position in ITCI in Q3 2015 and held it in 8 quarters. The position peaked at $144M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Voloridge Investment Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Voloridge Investment Management sold 1,093,738 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $144M.
  • Voloridge Investment Management first reported a position in Intra-Cellular Therapies Inc. in Q3 2015 and held it in 8 quarters.
  • Voloridge Investment Management's Intra-Cellular Therapies Inc. position peaked at $144M in Q1 2025.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Voloridge Investment Management's 13F filing for Q2 2025, filed 14 Aug 2025.